mHSPC shifts. PARP inhibitors and radioligands. AKT inhibitors. The evolving role of ARPIs in high-risk disease. The Uromigos take on prostate cancer in Episode 2 of their Year in Review — coming soon.

Episode 1 is LIVE. Renal oncology shifts, biomarker momentum, SBRT debates, and more. The Uromigos unpack 2025’s biggest RCC moments. Listen Now >>> https://t.co/fcbdHYd1gq

Adjuvant updates. Biomarkers rising. SBRT questions. Combination therapy in tough RCC settings. The @Uromigos unpack it all in their first Year in Review episode - coming Monday.

More physicians are rethinking their career paths — and diversification is becoming essential, not optional. 👩⚕️📈 Dr. Monique Nugent unpacks why doctors should start exploring non-clinical opportunities. #MedTwitter #CareerDevelopment https://t.co/hWPDFndTVH

🤖 AI ≠ autopilot. MarkAlain Dery, DO: AI is a “clinical co-pilot”—processing data, refining diagnoses & spotting nuances. AI can make care smarter if it stays a co-pilot. #AIinMedicine #DigitalHealth #FutureOfCare https://t.co/JzSLdaPE8p

💊 ART turned HIV from fatal ➡️ manageable. But suppressed ≠ cured. The hidden reservoir fuels aging, inflammation & lifelong treatment needs. A cure isn’t just science—it’s a moral imperative. 🌍❤️ #HIV #HIVcure #EndHIV #HealthEquity #GlobalHealth https://t.co/td01wKBofJ

TikTok skin care for kids may be harming—not helping. Findings: 🚫 Only 26% used SPF ⚠️ 11+ irritating actives/video 🤳 Often push “lighter, brighter” skin ideals Is this beauty or harm disguised as health? https://t.co/J95RuCuvbw #Skincare #Pediatrics #TikTok

IBD ≠ pneumonia risk—unless other factors are at play. A new study shows comorbidities (12x) and steroid use (2x) are the real drivers of pneumonia in IBD—not the disease itself. https://t.co/nMkZJ8btd8 #IBD #InfectionRisk #Pneumonia

⚠️ New study links central obesity to higher psoriasis risk 📏 Waist circumference may be more telling than BMI 🧬 Highlights need for targeted screening & prevention 🔗 https://t.co/5cBQ5tdSHZ #Psoriasis #Obesity #Inflammation #Dermatology #ChronicDisease

🚨 @US_FDA has approved #dupilumab for #bullouspemphigoid 🎯 18.3% achieved sustained remission 🧪 Less steroid use, less itch, better outcomes 🔗 https://t.co/UstLd3FDmW #Dermatology #FDAapproval

🐶 Can dogs help prevent eczema in kids with genetic risk? 🧬 New research says early-life dog exposure may reduce eczema risk—even in those genetically predisposed. 📖 Dive into the findings: https://t.co/Na06AZCkvp #Eczema #Pediatrics #AllergyPrevention #Genetics

👶 New study links paternal psychological distress to delays in early child development 🧠 Impacts seen as early as 12 months 💡 Highlights the need for paternal mental health screening 🔗 https://t.co/4odxUFg26P #ChildDevelopment #MentalHealth #Pediatrics #PublicHealth

🥼 Mediterranean vs. low-FODMAP: Which diet better supports IBS symptom control in clinical practice? 📊 New comparative data offers insights into efficacy and long-term feasibility. https://t.co/VvUXbmB32z #IBS #Gastroenterology #MedTwitter #NutritionScience #EvidenceBased

🎥 Did you know TikTok is reshaping conversations about #irritableboweldisease? 🌍 Patients are turning to social media to connect, learn, & find community. 🔗 Read more here: https://t.co/UbLDoy5UfQ #IBDAwareness #Crohns #UlcerativeColitis #Healthcare

🧠 REM sleep apnea may be more harmful than we thought—it's linked to white matter changes and cognitive decline. 😴 A deeper look into how sleep phases impact brain health. 🔗 https://t.co/TGeqkvk5py #SleepHealth #BrainResearch #REM #SleepApnea #Cognition

💊 71% of patients with sleep disorders preferred solriamfetol over modafinils in a real-world study. 🔄 Those who switched back cited better results or fewer side effects with modafinils. 🔗 Read more: https://t.co/G9FLwgAwEg #SleepHealth #Narcolepsy #Solriamfetol #Modafinil

🧬 A new study examines pembrolizumab plus lenvatinib in uterine carcinosarcoma 📊 Results were shared at #ASCO25, highlighting clinical benefit in select patients 🔗 https://t.co/j85O6u7gOo #UterineCancer #Immunotherapy #CancerResearch #ASCO25

🧬🔍 New insights into #uterine #leiomyosarcoma! A study presented at #ASCO25 analyzes the genetic profile of LMS using a national database. 📄 Read more: https://t.co/i8FSM2IvIu #UterineCancer #GenomicProfiling #CancerResearch #ASCO25

🧬 A new study from #ASCO25 explores neoadjuvant #pepinemab in #headandneckcancer treatment 🔬 Aims to prime #tumor immunity before surgical intervention 📈 Potentially enhancing patient outcomes through immune activation 🔗 Read more: https://t.co/154XIbpdYo

🔬 #ASCO25 📈 Concurrent chemoradiotherapy (CCRT) shows superior outcomes 🧪 CCRT outperforms radiotherapy and surgery in overall and progression-free survival 💡 Combining CCRT with other therapies offers comparable efficacy 🔗 Read more: https://t.co/z2UF5MlFBq